טוען...
A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer
Background: We evaluated the efficacy and safety of gemcitabine in combination with erlotinib and S-1 for the treatment of advanced pancreatic cancer. Methods: Chemotherapy-naïve patients with pathologically-proven locally advanced, recurrent, or metastatic pancreatic adenocarcinoma were assessed fo...
שמור ב:
| הוצא לאור ב: | J Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Ivyspring International Publisher
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7778528/ https://ncbi.nlm.nih.gov/pubmed/33403047 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.50514 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|